YMRC
BBIO icon

Yorktown Management & Research Company’s BridgeBio Pharma BBIO Stock Holding History

Yorktown Management & Research Company’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Buy
4,200
+950
+29% +$66.5K 0.19% 208
2026
Q1 		$241K Buy
+3,250
New +$236K 0.2% 192

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Yorktown Management & Research Company's BBIO Position: Q2 2026 in Review

Yorktown Management & Research Company increased its BridgeBio Pharma (BBIO) stake by 29% in Q2 2026, buying an estimated $66.5K and bringing the position to 4,200 shares worth $313K. The position accounts for 0.19% of the portfolio, ranked #208.

Yorktown Management & Research Company first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 204 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Yorktown Management & Research Company held 4,200 shares of BridgeBio Pharma worth $313K as of Q2 2026.
  • Yorktown Management & Research Company bought 950 BridgeBio Pharma shares in Q2 2026, an estimated $66.5K.
  • BridgeBio Pharma made up 0.19% of Yorktown Management & Research Company's portfolio in Q2 2026, its #208 holding.
  • Yorktown Management & Research Company first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • 204 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.